173 related articles for article (PubMed ID: 23948972)
1. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.
Romano E; Pradervand S; Paillusson A; Weber J; Harshman K; Muehlethaler K; Speiser D; Peters S; Rimoldi D; Michielin O
Clin Cancer Res; 2013 Oct; 19(20):5749-57. PubMed ID: 23948972
[TBL] [Abstract][Full Text] [Related]
2. Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells.
Lidsky M; Antoun G; Speicher P; Adams B; Turley R; Augustine C; Tyler D; Ali-Osman F
J Biol Chem; 2014 Oct; 289(40):27714-26. PubMed ID: 25063807
[TBL] [Abstract][Full Text] [Related]
3. The clinical response to vemurafenib in a patient with a rare BRAFV600DK601del mutation-positive melanoma.
Trudel S; Odolczyk N; Dremaux J; Toffin J; Regnier A; Sevestre H; Zielenkiewicz P; Arnault JP; Gubler B
BMC Cancer; 2014 Sep; 14():727. PubMed ID: 25265970
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells.
Wu CP; Sim HM; Huang YH; Liu YC; Hsiao SH; Cheng HW; Li YQ; Ambudkar SV; Hsu SC
Biochem Pharmacol; 2013 Feb; 85(3):325-34. PubMed ID: 23153455
[TBL] [Abstract][Full Text] [Related]
5. Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report.
Dooley AJ; Gupta A; Middleton MR
Target Oncol; 2016 Aug; 11(4):557-63. PubMed ID: 26857260
[TBL] [Abstract][Full Text] [Related]
6. Melanoma Expressed-CD70 Is Regulated by RhoA and MAPK Pathways without Affecting Vemurafenib Treatment Activity.
Pich C; Teiti I; Sarrabayrouse G; Gallardo F; Gence R; Tilkin-Mariamé AF
PLoS One; 2016; 11(2):e0148095. PubMed ID: 26828592
[TBL] [Abstract][Full Text] [Related]
7. Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest.
Acquavella N; Clever D; Yu Z; Roelke-Parker M; Palmer DC; Xi L; Pflicke H; Ji Y; Gros A; Hanada K; Goldlust IS; Mehta GU; Klebanoff CA; Crompton JG; Sukumar M; Morrow JJ; Franco Z; Gattinoni L; Liu H; Wang E; Marincola F; Stroncek DF; Lee CC; Raffeld M; Bosenberg MW; Roychoudhuri R; Restifo NP
Cancer Immunol Res; 2015 Jan; 3(1):37-47. PubMed ID: 25358764
[TBL] [Abstract][Full Text] [Related]
8. Resistance to vemurafenib can be reversible after treatment interruption: a case report of a metastatic melanoma patient.
Mackiewicz-Wysocka M; Krokowicz Ł; Kocur J; Mackiewicz J
Medicine (Baltimore); 2014 Dec; 93(27):e157. PubMed ID: 25501056
[TBL] [Abstract][Full Text] [Related]
9. In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation.
Ikediobi ON; Reimers M; Durinck S; Blower PE; Futreal AP; Stratton MR; Weinstein JN
Mol Cancer Ther; 2008 Jun; 7(6):1337-46. PubMed ID: 18524847
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide RNAi screen for genes regulating glycolytic response to vemurafenib in BRAF
Smith LK; Parmenter T; Gould CM; Madhamshettiwar PB; Sheppard KE; Simpson KJ; McArthur GA
Sci Data; 2020 Oct; 7(1):339. PubMed ID: 33046726
[TBL] [Abstract][Full Text] [Related]
11. High-resolution interrogation of functional elements in the noncoding genome.
Sanjana NE; Wright J; Zheng K; Shalem O; Fontanillas P; Joung J; Cheng C; Regev A; Zhang F
Science; 2016 Sep; 353(6307):1545-1549. PubMed ID: 27708104
[TBL] [Abstract][Full Text] [Related]
12. Genome-scale activation screen identifies a lncRNA locus regulating a gene neighbourhood.
Joung J; Engreitz JM; Konermann S; Abudayyeh OO; Verdine VK; Aguet F; Gootenberg JS; Sanjana NE; Wright JB; Fulco CP; Tseng YY; Yoon CH; Boehm JS; Lander ES; Zhang F
Nature; 2017 Aug; 548(7667):343-346. PubMed ID: 28792927
[TBL] [Abstract][Full Text] [Related]
13. Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer.
Oddo D; Siravegna G; Gloghini A; Vernieri C; Mussolin B; Morano F; Crisafulli G; Berenato R; Corti G; Volpi CC; Buscarino M; Niger M; Dunne PD; Rospo G; Valtorta E; Bartolini A; Fucà G; Lamba S; Martinetti A; Di Bartolomeo M; de Braud F; Bardelli A; Pietrantonio F; Di Nicolantonio F
Br J Cancer; 2017 Jul; 117(3):347-352. PubMed ID: 28654634
[TBL] [Abstract][Full Text] [Related]
14. Elucidating molecular mechanisms of acquired resistance to BRAF inhibitors in melanoma using a microfluidic device and deep sequencing.
Han J; Jung Y; Jun Y; Park S; Lee S
Genomics Inform; 2021 Mar; 19(1):e2. PubMed ID: 33840166
[TBL] [Abstract][Full Text] [Related]
15. Loss of the chromatin modifier Kdm2aa causes BrafV600E-independent spontaneous melanoma in zebrafish.
Scahill CM; Digby Z; Sealy IM; Wojciechowska S; White RJ; Collins JE; Stemple DL; Bartke T; Mathers ME; Patton EE; Busch-Nentwich EM
PLoS Genet; 2017 Aug; 13(8):e1006959. PubMed ID: 28806732
[TBL] [Abstract][Full Text] [Related]
16. Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway.
Shain AH; Garrido M; Botton T; Talevich E; Yeh I; Sanborn JZ; Chung J; Wang NJ; Kakavand H; Mann GJ; Thompson JF; Wiesner T; Roy R; Olshen AB; Gagnon A; Gray JW; Huh N; Hur JS; Busam KJ; Scolyer RA; Cho RJ; Murali R; Bastian BC
Nat Genet; 2015 Oct; 47(10):1194-9. PubMed ID: 26343386
[TBL] [Abstract][Full Text] [Related]
17. The Human Melanoma Proteome Atlas-Complementing the melanoma transcriptome.
Betancourt LH; Gil J; Sanchez A; Doma V; Kuras M; Murillo JR; Velasquez E; Çakır U; Kim Y; Sugihara Y; Parada IP; Szeitz B; Appelqvist R; Wieslander E; Welinder C; de Almeida NP; Woldmar N; Marko-Varga M; Eriksson J; Pawłowski K; Baldetorp B; Ingvar C; Olsson H; Lundgren L; Lindberg H; Oskolas H; Lee B; Berge E; Sjögren M; Eriksson C; Kim D; Kwon HJ; Knudsen B; Rezeli M; Malm J; Hong R; Horvath P; Szász AM; Tímár J; Kárpáti S; Horvatovich P; Miliotis T; Nishimura T; Kato H; Steinfelder E; Oppermann M; Miller K; Florindi F; Zhou Q; Domont GB; Pizzatti L; Nogueira FCS; Szadai L; Németh IB; Ekedahl H; Fenyö D; Marko-Varga G
Clin Transl Med; 2021 Jul; 11(7):e451. PubMed ID: 34323402
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy.
Ascierto ML; Makohon-Moore A; Lipson EJ; Taube JM; McMiller TL; Berger AE; Fan J; Kaunitz GJ; Cottrell TR; Kohutek ZA; Favorov A; Makarov V; Riaz N; Chan TA; Cope L; Hruban RH; Pardoll DM; Taylor BS; Solit DB; Iacobuzio-Donahue CA; Topalian SL
Clin Cancer Res; 2017 Jun; 23(12):3168-3180. PubMed ID: 28193624
[No Abstract] [Full Text] [Related]
19. A brief history of melanoma: from mummies to mutations.
Rebecca VW; Sondak VK; Smalley KS
Melanoma Res; 2012 Apr; 22(2):114-22. PubMed ID: 22395415
[TBL] [Abstract][Full Text] [Related]
20. Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma.
Jeck WR; Parker J; Carson CC; Shields JM; Sambade MJ; Peters EC; Burd CE; Thomas NE; Chiang DY; Liu W; Eberhard DA; Ollila D; Grilley-Olson J; Moschos S; Neil Hayes D; Sharpless NE
Pigment Cell Melanoma Res; 2014 Jul; 27(4):653-63. PubMed ID: 24628946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
